Tramadol is used for the treatment of
pain, and it is generally believed to activate the μ-
opioid receptor and inhibit
serotonin (5-HT) and
norepinephrine (NE) transporters. Recent findings from animal experiments suggest that
5-HT reuptake inhibition in brain is related to
pain reduction. However, there has been no report of
5-HT transporter (5-HTT) occupancy by
tramadol at clinical doses in humans. In the present study, we investigated 5-HTT occupancy by
tramadol in five subjects receiving various doses of
tramadol by using positron emission tomography (PET) scanning with the radioligand [
11C]DASB. Our data showed that mean 5-HTT occupancies in the thalamus by single doses of
tramadol were 34.7% at 50 mg and 50.2% at 100 mg. The estimated median effective dose (ED50) of
tramadol was 98.1 mg, and the plasma concentration was 0.33 μg/ml 2 h after its administration; 5-HTT occupancy by
tramadol was dose-dependent. We estimated 5-HTT occupancy at 78.7% upon taking an upper limit dose (400 mg) of
tramadol. The results of the present study support the finding that 5-HTT inhibition is involved in the mechanism underlying the
analgesic effect of
tramadol in humans, and a clinical dose of
tramadol sufficiently inhibits 5-HTT reuptake; this inhibition is similar to that shown by
selective serotonin reuptake inhibitors (
SSRIs).